Akebia Therapeutics (AKBA) Q1 2024 Earnings
AKBA·Reported May 9, 2024·Before market open
Akebia Therapeutics reported Q1 2024 revenue of $32.6M, missed analyst consensus of $49.5M by $16.8M. Diluted EPS came in at $-0.09.
Revenue
$32.6Mmissed by $16.8M
Consensus: $49.5MDiluted EPS
$-0.09met estimate
Consensus: $-0.09
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Akebia Therapeutics's Q1 2024 earnings report.
Akebia Therapeutics (AKBA) reported Q1 2024 earnings on May 9, 2024 before market open.
Akebia Therapeutics reported revenue of $32.6M and diluted EPS of $-0.09 for Q1 2024.
Revenue missed the consensus estimate of $49.5M by $16.8M. EPS beat the consensus estimate of $-0.09 by $0.00.
You can read the 10-Q periodic report (0001628280-24-021945) directly on SEC EDGAR. The filing index links above go to sec.gov.